BioLineRx and Hemispherian Unveil Promising Results for GLIX1 at SNO 2026

BioLineRx and Hemispherian Present Clinical Insights on GLIX1 at SNO 2026



In a recent presentation at the esteemed Society for Neuro-Oncology (SNO) Annual Meeting in 2026, BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS unveiled crucial findings from their ongoing Phase 1/2a clinical study of GLIX1. This novel treatment, aimed at tackling glioblastoma (GBM), has shown promising results across various models, raising hopes for patients with this aggressive form of cancer.

Advancements in the Phase 1/2a Study


The study, which is designed to evaluate the safety and effectiveness of GLIX1, commenced its fourth cohort, focusing on patients in a

Topics Other)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.